Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
Executive Summary
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program
You may also be interested in...
Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
Neurontin Ruling Is Guide For DoJ Off-Label Promotion Cases – Prosecutor
A recent ruling in the Neurontin "whistleblower" case lays the groundwork for future prosecutions involving off-label promotions under the False Claims Act, Philadelphia Assistant U.S. Attorney Virginia Gibson said Oct. 2 during an audioconference sponsored by the Pharmaceutical Compliance Forum